Cationic host defence peptides: multifaceted role in immune modulation and inflammation.
Choi. Ka-Yee KY; Chow. Leola N Y LN; Mookherjee. Neeloffer N
Key Findings
- Host defence peptides like LL-37 have both direct antimicrobial and broad immunomodulatory effects.
- LL-37 influences immunity through multiple receptors, signaling cascades, and transcription factors.
- Research is exploring LL-37 and synthetic analogs as potential treatments for immune‑mediated inflammatory disorders.
Practical Outcomes
- For biohackers, the take‑away is that LL-37 is a promising immune‑modulating molecule, but there are no established dosing protocols yet. Current evidence suggests potential benefits for inflammation control, but practical use should wait for clinical trials or validated supplement formulations.
Summary
LL-37 and similar antimicrobial peptides do more than kill germs – they also tweak the immune system and inflammation. Scientists are learning how these tiny proteins talk to immune cells, affect signaling pathways, and could be used to treat inflammatory diseases, but most of this knowledge comes from lab studies, not real‑world dosing guidelines.
Abstract
Host defence peptides (HDPs) are innate immune effector molecules found in diverse species. HDPs exhibit a wide range of functions ranging from direct antimicrobial properties to immunomodulatory effects. Research in the last decade has demonstrated that HDPs are critical effectors of both innate and adaptive immunity. Various studies have hypothesized that the antimicrobial property of certain HDPs may be largely due to their immunomodulatory functions. Mechanistic studies revealed that the role of HDPs in immunity is very complex and involves various receptors, signalling pathways and transcription factors. This review will focus on the multiple functions of HDPs in immunity and inflammation, with special reference to cathelicidins, e.g. LL-37, certain defensins and novel synthetic innate defence regulator peptides. We also discuss emerging concepts of specific HDPs in immune-mediated inflammatory diseases, including the potential use of cationic peptides as therapeutics for immune-mediated inflammatory disorders.
Study Information
pubmed
2012
2012-03-14T00:00:00.000Z
10.1159/000336630
234
95